Feldan Therapeutics and Elasmogen Announce Research Agreement with Amgen to Develop Intracellular Biologics

ABERDEEN, Scotland and QUEBEC CITY, Canada, May 9, 2017 /PRNewswire/ --

Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets

Elasmogen Ltd, focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announce a research collaboration with Amgen, to develop and deliver novel intracellular biologics. The collaboration combines the unique capabilities of Feldan's Shuttle platform and Elasmogen's soloMER™ technology to develop the delivery system and binding domains to two undisclosed intracellular targets for Amgen.

The Feldan Shuttle technology is a novel peptide-based delivery method that enables the highly efficient introduction of foreign proteins into cells. Elasmogen's soloMER's are the smallest naturally occurring binding domains. Their small size and robust nature, particularly the resistance to changes in pH and ability to bind in intracellular conditions makes them the perfect complement to Feldan's technology.

"Currently all approved biologic antibody therapeutics act on extracellular targets but intracellular delivery enables access to a much greater number of targets," said François-Thomas Michaud, CEO, Feldan Therapeutics. "Intracellular delivery and binding of biologics can bridge the gap between small molecules and biologics."

"This is an exciting opportunity to demonstrate the performance and capabilities of the combined Shuttle-soloMER technology. The expertise provided by Amgen will significantly accelerate the development of this potential new class of therapeutics," said Caroline Barelle, CEO, Elasmogen.

In 2016, Feldan and Elasmogen established an exclusive partnership for the development of intracellular biologics. Working together, their research teams have demonstrated both intracellular and intranuclear delivery of soloMER binding domains.

About Elasmogen: 

Elasmogen, a spin-out from the University of Aberdeen, is a drug discovery and development, biopharmaceutical company developing soloMERs, fully humanized, next generation, single chain biologics for auto-inflammatory diseases, ophthalmology, oncology and intracellular delivery. soloMERs are proprietary humanized clinical candidates derived from VNARS (variable new-antigen receptors) which exist naturally in sharks as high affinity binding domains. With a different ancestral origin from antibodies this example of 400 million year old convergent evolution places VNARs outside of the complex patent landscape that describes and protects antibody drug discovery. soloMERs are the smallest (9% of the size of an antibody) and most robust naturally occurring binding domain which makes them ideal for binding to intracellular targets. The Company's technology has been endorsed through partnerships with Almac, Amgen and Merck.  

Elasmogen is unique in its capacity to isolate and develop soloMERs, with a multi-layered IP position covering the platform, products and process including an exclusive license to over 20 patents granted in the US, Europe and other territories together with the entire know-how and VNAR pipeline from the Scottish Biologics Facility, University of Aberdeen. More information is available at www.Elasmogen.com  

About Feldan Therapeutics: 

Feldan Therapeutic is a Canadian company dedicated to the development of regenerative medicine therapeutic applications based on the Feldan Shuttle platform, a breakthrough peptide-based delivery method that allows the introduction of foreign proteins inside cells. The Feldan Shuttle overcomes delivery obstacles in therapeutic context by providing a safe and highly efficient approach that alleviates manipulation complexity and that is associated with low regulatory burden. The Shuttle platform has been successfully used to transfer active nucleases and transcription factors inside several types of cells; moreover, preliminary results in rodents suggest that the Shuttle has a promising potential for in vivo applications. Work is currently ongoing to further develop the Shuttle technology in order to promote the internalization of antibodies (or antibody-like domains) to modulate cellular pathways. In addition, Feldan has an in-house therapeutic pipeline centered on the generation of hyperactive NK cells for oncology applications.

More information is available at www.feldan.com

Company Contacts:
Elasmogen
Caroline Barelle, CEO, Elasmogen
Tel: +44-(0)-1224-438545
caroline.barelle@elasmogen.com

Katja Stout/ Sylvie Berrebi
Citigate Dewe Rogerson
Tel: +44-(0)-7984141186/+44-(0)-7795197271
elasmogen@citigatedr.co.uk

Feldan Therapeutics
François-Thomas Michaud, CEO
Feldan Therapeutics
Tel: +1-418-872-7277
ftmichaud@feldan.com

SOURCE Elasmogen